Description: Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company is headquartered in Calgary, Canada.
Home Page: www.resverlogix.com
4820 Richard Road SW
Calgary,
AB
T3E 6L1
Canada
Phone:
403 254 9252
Officers
| Name | Title |
|---|---|
| Mr. Aaron Bradley Cann C.A., CPA, CBV | Chief Financial Officer |
| Dr. Ewelina Kulikowski Ph.D. | Chief Scientific Officer |
| Dr. Michael Sweeney M.D. | Senior Vice President of Clinical Development |
| Mr. Donald J. McCaffrey | Co-Founder, Chairman, President, CEO & Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | April |
| Full Time Employees: | 0 |